<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02594865</url>
  </required_header>
  <id_info>
    <org_study_id>NL51918.100.14</org_study_id>
    <nct_id>NCT02594865</nct_id>
  </id_info>
  <brief_title>The Glycaemic Effects of Glucerna® in Critically Ill Patients.</brief_title>
  <acronym>GluCip</acronym>
  <official_title>Glucerna in Critically Ill Patients (GluCip Trial): Investigating the Glycaemic Effects of a Reduced-carbohydrate, Modified-fat, Fiber-containing Enteral Formula (Glucerna®) in Critically Ill Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PHJ van der Voort</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Onze Lieve Vrouwe Gasthuis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate whether the administration of Glucerna achieves less glycaemic variability,
      defined as the mean absolute glucose (MAG) change, and better glycaemic control compared to a
      standard high-carbohydrate enteral formula. Continuous glucose monitoring technology will be
      used to evaluate glycaemic variability and glycaemic control.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glucose variability</measure>
    <time_frame>72 hours</time_frame>
    <description>The primary outcome is the extent of glucose variability, defined as the mean absolute glucose (MAG) change (delta glucose/delta time) in mmol/l/hr.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Amount of insulin use</measure>
    <time_frame>72 hours</time_frame>
    <description>In units/day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time in target range</measure>
    <time_frame>72 hours</time_frame>
    <description>Defined as a glucose between 6-9 mmol/l in minutes/day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean glucose and standarddeviation</measure>
    <time_frame>72 hours</time_frame>
    <description>Defined as the mean sensor glucose and standarddeviation in mmol/l.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of severe hypoglycemic events</measure>
    <time_frame>72 hours</time_frame>
    <description>Hypoglycemic event is defined as a sensor glucose below 2.2 mmol/l.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of severe hypoglycemic events</measure>
    <time_frame>72 hours</time_frame>
    <description>Hypoglycemic event is defined as a sensor glucose below 2.2 mmol/l. Duration is measured in minutes/day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of severe hyperglycemic events</measure>
    <time_frame>72 hours</time_frame>
    <description>Hyperglycemic event is defined as a sensor glucose above 15.0 mmol/l.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of severe hyperglycemic events</measure>
    <time_frame>72 hours</time_frame>
    <description>Hyperglycemic event is defined as a sensor glucose above 15.0 mmol/l. Duration is measured in minutes/day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily calorie administration</measure>
    <time_frame>72 hours</time_frame>
    <description>Defined as amount of calories received per patient/day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily nutrient administration</measure>
    <time_frame>72 hours</time_frame>
    <description>Defined as amount of nutrients (carbohydrates, fat, proteins) received per patient/day.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Disorder of Glucose Regulation</condition>
  <arm_group>
    <arm_group_label>Glucerna</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Glucerna ® 1.5 kcal (Abbott, USA), the standard enteral formula used at our ICU and the investigational enteral feeding.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fresubin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fresubin ® Energy Fibre (Fresenius, UK), the control enteral feeding.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Glucerna</intervention_name>
    <description>Glucerna ® 1.5 kcal (Abbott, USA), the standard enteral formula used at our ICU and the investigational enteral feeding.</description>
    <arm_group_label>Glucerna</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Fresubin</intervention_name>
    <description>Fresubin ® Energy Fibre (Fresenius, UK), the control enteral feeding.</description>
    <arm_group_label>Fresubin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years;

          -  Patients with an anticipated stay of at least 48 hours of admission to the intensive
             care

          -  Expected to receive enteral feeding for at least 48 hrs

          -  Indication for glucose regulation with insulin (according to the current glucose
             treatment protocol)

          -  Patient or surrogate understands and signs informed consent document.

        Exclusion Criteria:

          -  Patients with pre-existing contraindications to enteral feeding or to placement of a
             continuous glucose monitoring system

          -  Patients previously randomised into the GluCip trial

          -  Any disease or condition which the investigator or treating physician feels would
             interfere with the trial or the safety of the patient.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter HJ van der Voort, Prof. dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Onze Lieve Vrouwe Gasthuis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Onze Lieve Vrouwe Gasthuis</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1091 AC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 16, 2015</study_first_submitted>
  <study_first_submitted_qc>October 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2015</study_first_posted>
  <last_update_submitted>June 24, 2016</last_update_submitted>
  <last_update_submitted_qc>June 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Onze Lieve Vrouwe Gasthuis</investigator_affiliation>
    <investigator_full_name>PHJ van der Voort</investigator_full_name>
    <investigator_title>Prof., MD, PhD, MSc</investigator_title>
  </responsible_party>
  <keyword>Enteral Nutrition</keyword>
  <keyword>Continuous Glucose Monitoring</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>April 4, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

